In the study for approval, Johnson & Johnson's (Ad26.COV2.S; COVID-19 Vaccine Janssen) showed an efficacy of approximately 65 percent and high protection against severe course of disease, after a single dose of vaccine.
However, according to current knowledge, a single dose of Johnson & Johnson's vaccine does not provide sufficient protection against the Omicron , which is currently dominant in Switzerland. It is therefore recommended to supplement the basic immunization with an . For the booster vaccination, an mRNA vaccine is also recommended. In certain cases, booster vaccination is also possible with the Johnson & Johnson vector vaccine.
How long the protection of the booster vaccination lasts is still unclear and is being continuously investigated.